{
  "id": [
    "32665127"
  ],
  "source": [
    "MED"
  ],
  "pmid": [
    "32665127"
  ],
  "pmcid": [
    "PMC7334951"
  ],
  "fullTextIdList": [
    {
      "fullTextId": [
        "PMC7334951"
      ]
    }
  ],
  "doi": [
    "10.1016/j.cytogfr.2020.07.010"
  ],
  "title": [
    "Are we fully exploiting type I Interferons in today's fight against COVID-19 pandemic?"
  ],
  "authorString": [
    "Aricò E, Bracci L, Castiello L, Gessani S, Belardelli F."
  ],
  "authorList": [
    {
      "author": [
        {
          "fullName": [
            "Aricò E"
          ],
          "firstName": [
            "Eleonora"
          ],
          "lastName": [
            "Aricò"
          ],
          "initials": [
            "E"
          ],
          "authorAffiliationsList": [
            {
              "authorAffiliation": [
                "FaBioCell, Core Facilities, Istituto Superiore di Sanità, Rome, Italy."
              ]
            }
          ]
        },
        {
          "fullName": [
            "Bracci L"
          ],
          "firstName": [
            "Laura"
          ],
          "lastName": [
            "Bracci"
          ],
          "initials": [
            "L"
          ],
          "authorId": [
            {
              "_": "0000-0002-2535-4353",
              "$": {
                "type": "ORCID"
              }
            }
          ],
          "authorAffiliationsList": [
            {
              "authorAffiliation": [
                "Department of Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy."
              ]
            }
          ]
        },
        {
          "fullName": [
            "Castiello L"
          ],
          "firstName": [
            "Luciano"
          ],
          "lastName": [
            "Castiello"
          ],
          "initials": [
            "L"
          ],
          "authorAffiliationsList": [
            {
              "authorAffiliation": [
                "FaBioCell, Core Facilities, Istituto Superiore di Sanità, Rome, Italy."
              ]
            }
          ]
        },
        {
          "fullName": [
            "Gessani S"
          ],
          "firstName": [
            "Sandra"
          ],
          "lastName": [
            "Gessani"
          ],
          "initials": [
            "S"
          ],
          "authorAffiliationsList": [
            {
              "authorAffiliation": [
                "Center for Gender-specific Medicine, Istituto Superiore di Sanità, Rome, Italy."
              ]
            }
          ]
        },
        {
          "fullName": [
            "Belardelli F"
          ],
          "firstName": [
            "Filippo"
          ],
          "lastName": [
            "Belardelli"
          ],
          "initials": [
            "F"
          ],
          "authorAffiliationsList": [
            {
              "authorAffiliation": [
                "Institute of Translational Pharmacology, Consiglio Nazionale delle Ricerche, Rome, Italy. Electronic address: filippo.belardelli@ift.cnr.it."
              ]
            }
          ]
        }
      ]
    }
  ],
  "authorIdList": [
    {
      "authorId": [
        {
          "_": "0000-0002-2535-4353",
          "$": {
            "type": "ORCID"
          }
        }
      ]
    }
  ],
  "dataLinksTagsList": [
    {
      "dataLinkstag": [
        "supporting_data",
        "altmetrics"
      ]
    }
  ],
  "journalInfo": [
    {
      "volume": [
        "54"
      ],
      "journalIssueId": [
        "3012384"
      ],
      "dateOfPublication": [
        "2020 Aug"
      ],
      "monthOfPublication": [
        "8"
      ],
      "yearOfPublication": [
        "2020"
      ],
      "printPublicationDate": [
        "2020-08-01"
      ],
      "journal": [
        {
          "title": [
            "Cytokine & growth factor reviews"
          ],
          "ISOAbbreviation": [
            "Cytokine Growth Factor Rev"
          ],
          "medlineAbbreviation": [
            "Cytokine Growth Factor Rev"
          ],
          "NLMid": [
            "9612306"
          ],
          "ISSN": [
            "1359-6101"
          ],
          "ESSN": [
            "1879-0305"
          ]
        }
      ]
    }
  ],
  "pubYear": [
    "2020"
  ],
  "pageInfo": [
    "43-50"
  ],
  "abstractText": [
    "Coronavirus disease 2019 (COVID-19) first emerged in late 2019 in China. At the time of writing, its causative agent SARS-CoV-2 has spread worldwide infecting over 9 million individuals and causing more than 460,000 deaths. In the absence of vaccines, we are facing the dramatic challenge of controlling COVID-19 pandemic. Among currently available drugs, type I Interferons (IFN-I) - mainly IFN-α and β -represent ideal candidates given their direct and immune-mediated antiviral effects and the long record of clinical use. However, the best modalities of using these cytokines in SARS-CoV-2 infected patients is a matter of debate. Here, we discuss how we can exploit the current knowledge on IFN-I system to tailor the most promising dosing, timing and route of administration of IFN-I to the disease stage, with the final aim of making these cytokines a valuable therapeutic strategy in today's fight against COVID-19 pandemic."
  ],
  "affiliation": [
    "FaBioCell, Core Facilities, Istituto Superiore di Sanità, Rome, Italy."
  ],
  "publicationStatus": [
    "ppublish"
  ],
  "language": [
    "eng"
  ],
  "pubModel": [
    "Print-Electronic"
  ],
  "pubTypeList": [
    {
      "pubType": [
        "review-article",
        "Review",
        "Journal Article"
      ]
    }
  ],
  "meshHeadingList": [
    {
      "meshHeading": [
        {
          "majorTopic_YN": [
            "N"
          ],
          "descriptorName": [
            "Humans"
          ]
        },
        {
          "majorTopic_YN": [
            "N"
          ],
          "descriptorName": [
            "Pneumonia, Viral"
          ],
          "meshQualifierList": [
            {
              "meshQualifier": [
                {
                  "abbreviation": [
                    "PC"
                  ],
                  "qualifierName": [
                    "prevention & control"
                  ],
                  "majorTopic_YN": [
                    "Y"
                  ]
                }
              ]
            }
          ]
        },
        {
          "majorTopic_YN": [
            "N"
          ],
          "descriptorName": [
            "Coronavirus Infections"
          ],
          "meshQualifierList": [
            {
              "meshQualifier": [
                {
                  "abbreviation": [
                    "PC"
                  ],
                  "qualifierName": [
                    "prevention & control"
                  ],
                  "majorTopic_YN": [
                    "Y"
                  ]
                }
              ]
            }
          ]
        },
        {
          "majorTopic_YN": [
            "N"
          ],
          "descriptorName": [
            "Interferon-alpha"
          ],
          "meshQualifierList": [
            {
              "meshQualifier": [
                {
                  "abbreviation": [
                    "TU"
                  ],
                  "qualifierName": [
                    "therapeutic use"
                  ],
                  "majorTopic_YN": [
                    "Y"
                  ]
                }
              ]
            }
          ]
        },
        {
          "majorTopic_YN": [
            "N"
          ],
          "descriptorName": [
            "Interferon-beta"
          ],
          "meshQualifierList": [
            {
              "meshQualifier": [
                {
                  "abbreviation": [
                    "TU"
                  ],
                  "qualifierName": [
                    "therapeutic use"
                  ],
                  "majorTopic_YN": [
                    "Y"
                  ]
                }
              ]
            }
          ]
        },
        {
          "majorTopic_YN": [
            "N"
          ],
          "descriptorName": [
            "Antiviral Agents"
          ],
          "meshQualifierList": [
            {
              "meshQualifier": [
                {
                  "abbreviation": [
                    "TU"
                  ],
                  "qualifierName": [
                    "therapeutic use"
                  ],
                  "majorTopic_YN": [
                    "Y"
                  ]
                }
              ]
            }
          ]
        },
        {
          "majorTopic_YN": [
            "N"
          ],
          "descriptorName": [
            "Immunotherapy"
          ],
          "meshQualifierList": [
            {
              "meshQualifier": [
                {
                  "abbreviation": [
                    "MT"
                  ],
                  "qualifierName": [
                    "methods"
                  ],
                  "majorTopic_YN": [
                    "N"
                  ]
                }
              ]
            }
          ]
        },
        {
          "majorTopic_YN": [
            "N"
          ],
          "descriptorName": [
            "Secondary Prevention"
          ],
          "meshQualifierList": [
            {
              "meshQualifier": [
                {
                  "abbreviation": [
                    "MT"
                  ],
                  "qualifierName": [
                    "methods"
                  ],
                  "majorTopic_YN": [
                    "N"
                  ]
                }
              ]
            }
          ]
        },
        {
          "majorTopic_YN": [
            "N"
          ],
          "descriptorName": [
            "Pandemics"
          ],
          "meshQualifierList": [
            {
              "meshQualifier": [
                {
                  "abbreviation": [
                    "PC"
                  ],
                  "qualifierName": [
                    "prevention & control"
                  ],
                  "majorTopic_YN": [
                    "Y"
                  ]
                }
              ]
            }
          ]
        },
        {
          "majorTopic_YN": [
            "N"
          ],
          "descriptorName": [
            "Betacoronavirus"
          ],
          "meshQualifierList": [
            {
              "meshQualifier": [
                {
                  "abbreviation": [
                    "DE"
                  ],
                  "qualifierName": [
                    "drug effects"
                  ],
                  "majorTopic_YN": [
                    "Y"
                  ]
                }
              ]
            }
          ]
        }
      ]
    }
  ],
  "keywordList": [
    {
      "keyword": [
        "Immunomodulation",
        "Coronavirus",
        "Type I interferons",
        "Antiviral Therapy",
        "Antiviral Immune Response",
        "Beta Interferon",
        "Covid-19",
        "Sars-cov-2",
        "Mucosal Treatments"
      ]
    }
  ],
  "chemicalList": [
    {
      "chemical": [
        {
          "name": [
            "Antiviral Agents"
          ],
          "registryNumber": [
            "0"
          ]
        },
        {
          "name": [
            "Interferon-alpha"
          ],
          "registryNumber": [
            "0"
          ]
        },
        {
          "name": [
            "Interferon-beta"
          ],
          "registryNumber": [
            "77238-31-4"
          ]
        }
      ]
    }
  ],
  "subsetList": [
    {
      "subset": [
        {
          "code": [
            "IM"
          ],
          "name": [
            "Index Medicus"
          ]
        }
      ]
    }
  ],
  "fullTextUrlList": [
    {
      "fullTextUrl": [
        {
          "availability": [
            "Subscription required"
          ],
          "availabilityCode": [
            "S"
          ],
          "documentStyle": [
            "doi"
          ],
          "site": [
            "DOI"
          ],
          "url": [
            "https://doi.org/10.1016/j.cytogfr.2020.07.010"
          ]
        },
        {
          "availability": [
            "Open access"
          ],
          "availabilityCode": [
            "OA"
          ],
          "documentStyle": [
            "html"
          ],
          "site": [
            "Europe_PMC"
          ],
          "url": [
            "https://europepmc.org/articles/PMC7334951"
          ]
        },
        {
          "availability": [
            "Open access"
          ],
          "availabilityCode": [
            "OA"
          ],
          "documentStyle": [
            "pdf"
          ],
          "site": [
            "Europe_PMC"
          ],
          "url": [
            "https://europepmc.org/articles/PMC7334951?pdf=render"
          ]
        }
      ]
    }
  ],
  "isOpenAccess": [
    "Y"
  ],
  "inEPMC": [
    "Y"
  ],
  "inPMC": [
    "N"
  ],
  "hasPDF": [
    "Y"
  ],
  "hasBook": [
    "N"
  ],
  "hasSuppl": [
    "Y"
  ],
  "citedByCount": [
    "0"
  ],
  "hasData": [
    "Y"
  ],
  "hasReferences": [
    "Y"
  ],
  "hasTextMinedTerms": [
    "Y"
  ],
  "hasDbCrossReferences": [
    "N"
  ],
  "hasLabsLinks": [
    "Y"
  ],
  "authMan": [
    "N"
  ],
  "epmcAuthMan": [
    "N"
  ],
  "nihAuthMan": [
    "N"
  ],
  "hasTMAccessionNumbers": [
    "Y"
  ],
  "tmAccessionTypeList": [
    {
      "accessionType": [
        "nct"
      ]
    }
  ],
  "dateOfCompletion": [
    "2020-09-28"
  ],
  "dateOfCreation": [
    "2020-07-16"
  ],
  "firstIndexDate": [
    "2020-07-16"
  ],
  "fullTextReceivedDate": [
    "2020-07-12"
  ],
  "dateOfRevision": [
    "2020-09-28"
  ],
  "electronicPublicationDate": [
    "2020-07-04"
  ],
  "firstPublicationDate": [
    "2020-07-04"
  ]
}